0000000000219187

AUTHOR

Daniela Barana

showing 2 related works from this author

Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement

2021

An expert consensus panel convened by the Italian Association for Inherited and Familial Gastrointestinal Tumors (Associazione Italiana per lo Studio della Familiarita ed Ereditarieta dei Tumori Gastrointestinali, AIFEG) reviewed the literature and agreed on a number of position statements regarding the definition and management of polyposis coli without an identified pathogenic mutation on the APC or MUTYH genes, defined in the document as NAMP (non-APC/MUTYH polyposis).

Oncologymedicine.medical_specialtyGastrointestinal tumorsColorectal cancerSurgical ManagementColorectal polyposisGermline03 medical and health sciencesCancer Genetic0302 clinical medicineMUTYHInternal medicinemedicineCancer GeneticsPolyposis coliHepatologyPathogenic mutationbusiness.industryColorectal polyposis not associated with APC/MUTYH mutationPolyposis management guidelineGastroenterologyExpert consensusEndoscopic surveillancemedicine.diseaseColorectal cancerConsensus development conference030220 oncology & carcinogenesisCancer Genetics; Colorectal cancer; Colorectal polyposis not associated with APC/MUTYH mutation; Consensus development conference; Endoscopic surveillance; Polyposis management guideline; Surgical Management030211 gastroenterology & hepatologybusiness
researchProduct

Whole-exome sequencing and targeted gene sequencing provide insights into the role ofPALB2as a male breast cancer susceptibility gene

2016

BACKGROUND Male breast cancer (MBC) is a rare disease whose etiology appears to be largely associated with genetic factors. BRCA1 and BRCA2 mutations account for about 10% of all MBC cases. Thus, a fraction of MBC cases are expected to be due to genetic factors not yet identified. To further explain the genetic susceptibility for MBC, whole-exome sequencing (WES) and targeted gene sequencing were applied to high-risk, BRCA1/2 mutation–negative MBC cases. METHODS Germ-line DNA of 1 male and 2 female BRCA1/2 mutation–negative breast cancer (BC) cases from a pedigree showing a first-degree family history of MBC was analyzed with WES. Targeted gene sequencing for the validation of WES results w…

0301 basic medicineCancer genome sequencingProbandGeneticsCancer ResearchPALB2Nonsense mutationCancerBiologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncology030220 oncology & carcinogenesisMale breast cancermedicineskin and connective tissue diseasesExome sequencingCancer
researchProduct